Read our Recent Headlines


Jul 19, 2019 by Dave Sobek

July 19th Biotech Update

I am back and need to catch up on the overall market and some sector news. I do want to focus today on a stock we all know and will.

Share 0 Comments Read more
Jul 10, 2019 by Dave Sobek

July 10th Biotech Update

The market is in an odd position in that it is doing well with macro having faded into the background. I would keep an eye on the Iran situation flaring.

Jul 09, 2019 by Dave Sobek

July 9 Biotech Update

I am back from vacation and have a couple of days to get as much work done before I am taking care of some family issues. I should have some.

Jul 01, 2019 by Joe Gantoss

DMD Data by Giant Pharma Pfizer Kept Sarepta In the Driver Seat with Superior Drug

Pfizer (PFE) presented its first set of data (n=6) from the mini-dystrophin gene therapy for DMD (PF-06939926) at the PPMD conference on June 28th. Much speculations surrounded Pfizer’s decision to.

Jun 28, 2019 by Dave Sobek

June 28th Biotech Update

A good finish to the week so far in the sector. I will try and keep this quick and to the point as it is a little delayed because of.

Jun 27, 2019 by Dave Sobek

June 27 Biotech Update

A good start to the morning for the sector, although it seems mostly in line with the broader markets. Given the performance the past couple days, however, I am happy.

Jun 25, 2019 by Dave Sobek

June 25 Biotech Update

So that was unexpected. First, the market is down and sector is higher. Second, we got another large merger to digest. Obviously I will focus on the deal and its.

More From All Reports

Introduction


[videojs width="640" preload="auto" ogg="https://s3.amazonaws.com/chimeraresearchgroup.com/video/640ogg.ogg" webm="https://s3.amazonaws.com/chimeraresearchgroup.com/video/640webm.webm" mp4="https://s3.amazonaws.com/chimeraresearchgroup.com/video/640mp4.mp4"]

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!


      Join      

 Learn More